Quarterly ResultMay 6, 2026, 07:23 AM
Lifecore Biomedical Q1 Revenue $23.2M, Net Loss $15.0M
AI Summary
Lifecore Biomedical reported first-quarter 2026 revenues of $23.2 million, a 34% decrease year-over-year, with a net loss of $15.0 million. Adjusted EBITDA also declined to $1.0 million from $5.7 million in the prior year. Despite the financial declines, the company reaffirmed its 2026 guidance for revenue ($120-$125 million) and Adjusted EBITDA ($20.5-$25 million), citing successful execution of growth strategies, new program signings, and ongoing cost containment initiatives.
Key Highlights
- Q1 2026 revenues decreased 34% to $23.2 million from $35.2 million in Q1 2025.
- Net loss for Q1 2026 was $15.0 million, or $0.43 per diluted share.
- Adjusted EBITDA for Q1 2026 was $1.0 million, down from $5.7 million in Q1 2025.
- Gross profit margin for Q1 2026 was 19%, a 9% decrease from 28% in Q1 2025.
- Operating expenses decreased 52% to $9.1 million in Q1 2026.
- Cash from operations was $4.7 million and free cash flow was $3.6 million in Q1 2026.
- Signed three new commercial site transfer programs in Q1 2026.
- Reaffirmed 2026 revenue guidance of $120-$125 million and Adjusted EBITDA of $20.5-$25 million.
Price Impact
More from LFCR